

Richard Ceska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3612579/publications.pdf>

Version: 2024-02-01

113
papers

7,537
citations

147801

31
h-index

51608

86
g-index

141
all docs

141
docs citations

141
times ranked

7541
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. <i>Frontiers in Genetics</i> , 2022, 13, 849008. | 2.3 | 4 |
| 2 | Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR α Modulator, in European Patients on Statin Therapy. <i>Diabetes Care</i> , 2022, 45, 898-908. | 8.6 | 17 |
| 3 | Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622. | 7.3 | 35 |
| 4 | Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics. <i>Frontiers in Genetics</i> , 2022, 13, 849267. | 2.3 | 1 |
| 5 | PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology. <i>Current Atherosclerosis Reports</i> , 2022, , 1. | 4.8 | 6 |
| 6 | An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020, 5, 709. | 6.1 | 63 |
| 7 | Statin Intolerance in Clinical Practice. <i>Current Atherosclerosis Reports</i> , 2020, 22, 27. | 4.8 | 4 |
| 8 | Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719. | 7.1 | 17 |
| 9 | The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case-Control Study. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 555-562. | 3.8 | 10 |
| 10 | The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. <i>Current Atherosclerosis Reports</i> , 2019, 21, 36. | 4.8 | 13 |
| 11 | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM α) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71. | 6.8 | 104 |
| 12 | Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes. <i>Folia Biologica</i> , 2019, 65, 188-194. | 0.6 | 2 |
| 13 | Body Adiposity Changes After Lifestyle Interventions in Children/Adolescents and the NYD-SP18 and TMEM18 Variants. <i>Medical Science Monitor</i> , 2018, 24, 7493-7498. | 1.1 | 7 |
| 14 | Comments on the most important and recent studies involving PCSK9i. <i>Vnitřní Lekarství</i> , 2018, 64, 1137-1141. | 0.2 | 0 |
| 15 | A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. <i>Archives of Medical Science</i> , 2017, 4, 705-710. | 0.9 | 9 |
| 16 | ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS. <i>Physiological Research</i> , 2017, 66, S85-S90. | 0.9 | 6 |
| 17 | Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project. <i>Physiological Research</i> , 2017, 66, S1-S9. | 0.9 | 21 |
| 18 | Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1580. | 7.4 | 420 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Effect of APOE genotype on LDL cholesterol levels in FH and FDB patients: Is there sex-specifically protective genotype?. <i>Atherosclerosis</i> , 2016, 252, e40. | 0.8 | 1 |
| 20 | Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144. | 1.8 | 32 |
| 21 | Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. <i>Clinica Chimica Acta</i> , 2016, 454, 119-123. | 1.1 | 15 |
| 22 | Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23. | 0.9 | 311 |
| 23 | Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499. | 27.0 | 1,838 |
| 24 | FH homozygote without cardiovascular disease at the age of 40. <i>Atherosclerosis</i> , 2015, 241, e112. | 0.8 | 0 |
| 25 | Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. <i>European Journal of Internal Medicine</i> , 2015, 26, 367-368. | 2.2 | 11 |
| 26 | Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955. | 2.4 | 117 |
| 27 | Statin Intolerance: the Clinician's Perspective. <i>Current Atherosclerosis Reports</i> , 2015, 17, 69. | 4.8 | 43 |
| 28 | ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015, 36, ehv370. | 2.2 | 395 |
| 29 | SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population. <i>Medical Science Monitor</i> , 2015, 21, 1454-1459. | 1.1 | 24 |
| 30 | The Impact of Physical Activity and Dietary Measures on the Biochemical and Anthropometric Parameters in Obese Children. Is There Any Genetic Predisposition?. <i>Central European Journal of Public Health</i> , 2015, 23, S62-S66. | 1.1 | 10 |
| 31 | Treatment of Hypertriglyceridemia: a Review of Current Options. <i>Physiological Research</i> , 2015, 64, S331-S340. | 0.9 | 22 |
| 32 | Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. <i>Current Pharmaceutical Design</i> , 2015, 21, 1180-1184. | 1.9 | 1 |
| 33 | Ivabradine in Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2435-2435. | 27.0 | 16 |
| 34 | Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal. <i>Current Atherosclerosis Reports</i> , 2014, 16, 463. | 4.8 | 2 |
| 35 | Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870. | 7.4 | 422 |
| 36 | A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 370, 1809-1819. | 27.0 | 607 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Statins, Glycemia, and Diabetes Mellitus: Another Point of View. <i>Current Atherosclerosis Reports</i> , 2014, 16, 458. | 4.8 | 4 |
| 38 | Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. <i>Cor Et Vasa</i> , 2014, 56, e133-e139. | 0.1 | 7 |
| 39 | Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 455-463. | 11.4 | 84 |
| 40 | The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15. | 1.2 | 83 |
| 41 | Fifteen years of active search for patients with familial hypercholesterolemia in the Czech Republic. <i>Atherosclerosis</i> , 2014, 235, e197. | 0.8 | 1 |
| 42 | SLCO1B1 transporter polymorphism is not associated with risk of myopathy in Czech population. <i>Atherosclerosis</i> , 2014, 235, e256. | 0.8 | 0 |
| 43 | Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study. <i>Atherosclerosis</i> , 2014, 235, e12. | 0.8 | 0 |
| 44 | Rosiglitazone Influences the Expression of Leukocyte Adhesion Molecules and CD14 Receptor in Type 2 Diabetes Mellitus Patients. <i>Physiological Research</i> , 2014, 63, S293-S298. | 0.9 | 6 |
| 45 | Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management. <i>Physiological Research</i> , 2014, 63, S327-S334. | 0.9 | 45 |
| 46 | FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention. <i>Clinical Biochemistry</i> , 2013, 46, 313-316. | 1.9 | 39 |
| 47 | Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145. <i>European Heart Journal</i> , 2013, 34, P681-P681. | 2.2 | 1 |
| 48 | Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1232-1238. | 8.6 | 372 |
| 49 | Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. <i>Journal of Applied Biomedicine</i> , 2012, 10, 19-28. | 1.7 | 4 |
| 50 | APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, e22-e23. | 2.6 | 4 |
| 51 | Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. <i>PLoS ONE</i> , 2012, 7, e49006. | 2.5 | 190 |
| 52 | Impact of Variants Within Seven Candidate Genes on Statin Treatment Efficacy. <i>Physiological Research</i> , 2012, 61, 609-617. | 0.9 | 20 |
| 53 | Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. <i>Neuroendocrinology Letters</i> , 2012, 33 Suppl 2, 22-5. | 0.2 | 6 |
| 54 | Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. <i>Clinica Chimica Acta</i> , 2011, 412, 920-924. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. <i>Current Medical Research and Opinion</i> , 2011, 27, 1551-1562. | 1.9 | 55 |
| 56 | Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels. <i>Clinical Biochemistry</i> , 2010, 43, 754-758. | 1.9 | 4 |
| 57 | Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2010, 64, 727-738. | 1.7 | 27 |
| 58 | Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. <i>Annals of Medicine</i> , 2010, 42, 447-464. | 3.8 | 49 |
| 59 | Impact of apolipoprotein A5 variants on statin treatment efficacy. <i>Pharmacogenomics</i> , 2009, 10, 945-950. | 1.3 | 38 |
| 60 | The apo(a) gene (TTTTA) _n promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10. <i>Clinica Chimica Acta</i> , 2009, 405, 39-42. | 1.1 | 6 |
| 61 | MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. <i>Human Genetics</i> , 2008, 124, 553-555. | 3.8 | 28 |
| 62 | The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K. | 1.6 | 371 |
| 63 | Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1088-1092. | 3.4 | 42 |
| 64 | Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. <i>Medical Hypotheses</i> , 2008, 70, 199-200. | 1.5 | 2 |
| 65 | IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. <i>Atherosclerosis Supplements</i> , 2008, 9, 40. | 1.2 | 2 |
| 66 | APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 773-7. | 2.3 | 12 |
| 67 | The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335. | 2.0 | 227 |
| 68 | Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. <i>Physiological Research</i> , 2008, 57, 919-925. | 0.9 | 10 |
| 69 | Clinical implications of the metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S2-S4. | 2.0 | 18 |
| 70 | Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. <i>Nutrition Research</i> , 2007, 27, 181-185. | 2.9 | 1 |
| 71 | Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. <i>Clinica Chimica Acta</i> , 2007, 376, 77-81. | 1.1 | 13 |
| 72 | PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES. <i>Atherosclerosis Supplements</i> , 2007, 8, 69. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels. <i>Clinical Biochemistry</i> , 2007, 40, 802-805. | 1.9 | 3 |
| 74 | Mo-P6:430 Lipoprotein (A), its relation to gene control regions. <i>Atherosclerosis Supplements</i> , 2006, 7, 140-141. | 1.2 | 0 |
| 75 | We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2006, 7, 371. | 1.2 | 0 |
| 76 | Is it safe to combine PPAR agonists? A lesson from muraglitazar. <i>Medical Hypotheses</i> , 2006, 67, 669. | 1.5 | 0 |
| 77 | Hypertriglyceridemia: Interaction between APOE and APOAV Variants. <i>Clinical Chemistry</i> , 2005, 51, 1311-1313. | 3.2 | 14 |
| 78 | Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2005, 183, 367-368. | 0.8 | 7 |
| 79 | W15-P-006 Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2005, 6, 98. | 1.2 | 0 |
| 80 | T06-P-019 Apolipoprotein E gene polymorphism in the Mongolian population. <i>Atherosclerosis Supplements</i> , 2005, 6, 169. | 1.2 | 1 |
| 81 | Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. <i>Psychiatry Research</i> , 2005, 133, 197-203. | 3.3 | 78 |
| 82 | New Strategies in the Treatment of Dyslipidemia: Do We Know How?. <i>Seminars in Vascular Medicine</i> , 2004, 4, 305-310. | 2.1 | 0 |
| 83 | Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. <i>European Journal of Pharmacology</i> , 2004, 493, 183-189. | 3.5 | 35 |
| 84 | Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. <i>International Congress Series</i> , 2004, 1262, 458-461. | 0.2 | 2 |
| 85 | PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <i>Atherosclerosis</i> , 2003, 166, 195-196. | 0.8 | 8 |
| 86 | Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2003, 166, 197-198. | 0.8 | 8 |
| 87 | T-1131â†C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. <i>Atherosclerosis</i> , 2003, 167, 369-370. | 0.8 | 48 |
| 88 | Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. <i>American Heart Journal</i> , 2003, 146, 110A-115A. | 2.7 | 22 |
| 89 | Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. <i>American Heart Journal</i> , 2003, 146, 1060-1063. | 2.7 | 26 |
| 90 | Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. <i>American Journal of Cardiology</i> , 2003, 92, 337-341. | 1.6 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Increase of inflammatory state in overweight adults with combined hyperlipidemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003, 13, 227-231. | 2.6 | 7 |
| 92 | Ser19->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. <i>Journal of Medical Genetics</i> , 2003, 40, 105e-105. | 3.2 | 25 |
| 93 | Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction. <i>Experimental and Clinical Cardiology</i> , 2003, 8, 151-4. | 1.3 | 6 |
| 94 | Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. <i>Physiological Research</i> , 2003, 52, 439-45. | 0.9 | 21 |
| 95 | Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002, 144, G1-G8. | 2.7 | 11 |
| 96 | Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002, 144, E6. | 2.7 | 56 |
| 97 | Nitroglycerin Induced Syncope Occurs in Subjects with Delayed Phase Shift of Baroreflex Action. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 828-832. | 1.2 | 7 |
| 98 | Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial "FAT"). <i>Cardiovascular Research</i> , 2001, 52, 290-298. | 3.8 | 131 |
| 99 | Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. <i>Nutrition</i> , 2001, 17, 721-723. | 2.4 | 57 |
| 100 | Flow-Dependent Vasomotor Dysfunction of the Popliteal Artery Related to Common Carotid Artery Intima-Media Thickness. <i>Angiology</i> , 2001, 52, 689-695. | 1.8 | 1 |
| 101 | Serum leptin levels in patients with hyperlipidemias. <i>Nutrition</i> , 2000, 16, 429-433. | 2.4 | 26 |
| 102 | The independent correlation of the impact of lipoprotein(a) levels and apolipoprotein E polymorphism on carotid artery intima thickness. <i>Atherosclerosis</i> , 2000, 151, 311. | 0.8 | 0 |
| 103 | Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2000, 89, 1023-1024. | 1.5 | 5 |
| 104 | Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. <i>Journal of Clinical Investigation</i> , 2000, 106, 1263-1270. | 8.2 | 295 |
| 105 | Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report 1. <i>Journal of Internal Medicine</i> , 1999, 246, 235-236. | 6.0 | 6 |
| 106 | Apolipoprotein E polymorphism in patients with different types of hyperlipidemia. <i>Atherosclerosis</i> , 1999, 144, 21. | 0.8 | 0 |
| 107 | ApoE genotype is not associated with variations in bone mineral density. <i>Atherosclerosis</i> , 1999, 144, 103-104. | 0.8 | 8 |
| 108 | Type III hyperlipoproteinaemia in patient with severe hypothyroidism accompanied by primary amenorrhoea. <i>Atherosclerosis</i> , 1999, 144, 158. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Use of the D19S394 tetranucleotide repeat in the diagnosis of familial hypercholesterolemia. <i>Atherosclerosis</i> , 1999, 144, 195-196. | 0.8 | 0 |
| 110 | Editorial. <i>American Journal of Cardiology</i> , 1998, 81, 912-917. | 1.6 | 187 |
| 111 | Decreasing Common Carotid Artery Intimal Thickness During Hypolipidemic Therapy. <i>Angiology</i> , 1997, 48, 761-767. | 1.8 | 5 |
| 112 | 1.P.161 The effect of stain therapy on common carotid artery intimal thickness in patients with familial hyperlipidemia. <i>Atherosclerosis</i> , 1997, 134, 50. | 0.8 | 0 |
| 113 | 2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients. <i>Atherosclerosis</i> , 1997, 134, 110-111. | 0.8 | 0 |